Quarterly ResultMay 11, 2026, 04:19 PM
AbCellera Reports Positive ABCL635 Phase 1 Data; Q1 Net Loss $43.2M
AI Summary
AbCellera Biologics Inc. announced its Q1 2026 financial and operational results, reporting a net loss of $43.2 million, an improvement from $45.6 million in Q1 2025, and revenue of $8.3 million, up from $4.2 million. The company also released positive interim Phase 1 data for ABCL635, its antibody for vasomotor symptoms, highlighting a favorable tolerability profile, potential for once-monthly dosing, and strong target engagement. AbCellera ended the quarter with approximately $655 million in total available liquidity to execute its strategy.
Key Highlights
- ABCL635 Phase 1 data showed favorable tolerability with no liver toxicity.
- ABCL635 exhibited a pharmacokinetic profile supporting once-monthly subcutaneous dosing.
- ABCL635 demonstrated strong and sustained suppression of testosterone, FSH, and LH biomarkers.
- Net loss for Q1 2026 was $43.2 million, an improvement from $45.6 million in Q1 2025.
- Total revenue for Q1 2026 increased to $8.3 million from $4.2 million in Q1 2025.
- Research & Development expenses rose to $46.7 million from $42.5 million in Q1 2025.
- Sales, General & Administrative expenses decreased to $12.3 million from $19.1 million in Q1 2025.
- Total available liquidity at quarter-end was approximately $655 million.